A ADVANCED JOURNAL IN ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING TRENDS IN BIOLOGICAL SCIENCES
Open Journal

Review

Machine Learning and Artificial Intelligence in the Pharmaceutical Sector

Abhishek R. Mali; Amritha G. Nambiar; Ashish K. Agrawal; Dinesh Kumar*

Department of Pharmaceutical Engineering and Technology, IIT (BHU), Varanasi, India

***Corresponding author**
Dinesh Kumar
Department of Pharmaceutical Engineering and Technology, IIT (BHU), Varanasi, India

Article information
Received: April 11th, 2022; **Revised:** July 2nd, 2022; **Accepted:** July 31st, 2022; **Published:** September 16th, 2022

Cite this article
Mali AR, Nambiar AG, Agrawal AK, Kumar D. Machine learning and artificial intelligence in the pharmaceutical sector. 2022; 1(1).
doi: https://doi.org/10.70705/ppp.bioai.2022.v01.i01.pp9-13

ABSTRACT

Artificial intelligence (AI) and machine learning (ML) are being discussed in this study along with their present and future uses in the pharmaceutical sector. Drug research, development, and decision making are greatly aided by AI and ML methodologies, thanks to the amount of high-quality data. Innovations in AI and ML give rise to Industry 4.0 and Continuous Manufacturing. The pharmaceutical sector will inevitably undergo changes due to the fast emergence of new technology. Various pharmaceutical processes, including drug repurposing, clinical research, overall productivity, and advanced and future pharmaceutical employment, may affect these areas and more. When combined with smart PAT (process analytical technology) tools, these cutting-edge technologies will cause a shift in pharmaceutical production from batch to continuous. Integrated, automated, and self-organizing manufacturing technologies are the hallmarks of business 4.0 as they pertain to the pharmaceutical business. In order to strengthen research, regional development, and nation-building, cluster-based research was also the subject of this study.

Keywords
Artificial intelligence; Machine learning; Continuous manufacturing; Industry 4.0.

INTRODUCTION

Artificial intelligence and machine learning have significantly influenced the pharmaceutical and consumer healthcare industries. Artificial intelligence is a computer technology discipline that analyses enormous amounts of data in the medical field. Their ability to leverage meaningful correlations within a data collection can be helpful in diagnosis, therapy, selecting individuals for clinical trials, pharmaceutical production, and making predictions. Artificial intelligence's primary benefit is that it lowers drug development expenses, improves returns on investment, and possibly even lowers end-user cost.1 Practically all manufacturing processes have been done batch-wise in the past. Several pharmaceutical start-ups have recently started employing continuous manufacturing strategies to synthesize small molecule drugs, which can deliver over batch processing.2

Exploiting emerging technologies, Pharma Industry 4.0 improves long-term potential generation to a more flexible, innovative, and personalized pharma industry, allowing pharma firms to obtain long-term benefits in the marketplace. A much more long-term solution drug supply chain (DSC) needs to be developed to correspond upcoming management and control. To produce the next-generation medicines, pharmaceutical occupations have also begun to evolve from traditional careers to advanced careers. The scope of pharmaceutical research-based employment is expanding as professional prospects develop. As technology advances, cutting-edge and future job choices emerge, with the potential to enhance significantly pharmaceutical industrial production and bring the next generation of drugs to market through new research.3,4

Cluster-based research is increasing in regional areas in coordination with local institutes and industries. Cluster-based research increases market concentration and competition for all market participants. As cluster-based pharmaceutical research supporting manufacturing has become more prevalent in Ireland, the country's pharmaceutical industry statistics are becoming more impressive.5

AI in the pharma industry

According to some experts, by 2025, over half of all global healthcare corporations will have implemented AI plans, and it will be critical for how businesses operate in the future. Top pharmaceutical corporations partner with AI vendors for research & development and overall drug discovery and incorporate AI technology into their production processes. According to surveys, roughly 62% of healthcare organizations consider investing in AI soon, and 72% of busi-

nesses feel AI will be critical to their future operations.6,7

Present scenario of AI in pharma

The usage of AI and ML technologies, according to researchers, enhances decision-making, maximizes innovation, increases the efficiency of research/ clinical trials, and creates useful new tools for physicians, consumers, insurers, and regulators. Roche, Pfizer, Merck, AstraZeneca, GSK, Sanofi, AbbVie, Bristol-Myers Squibb, and Johnson & Johnson are among the top pharmaceutical corporations that have already partnered with or purchased AI technologies. The Massachusetts Institute of Technology has launched a Machine Learning based on Pharmaceutical Research and Synthesis program teamed with Novartis and Pfizer in 2018 to change medication design and production. The consortium intends to bridge the gap between MIT's machine learning research and drug discovery research by bringing together researchers and industry to identify and solve the most pressing issues.8

GSK also formed a partnership with Cloud Pharmaceuticals to speed up the development of new medication candidates. GSK and Vir Biotechnology teamed in April 2020 to improve COVID-19 drug discovery using CRISPR and AI. Roche and Owkin, a medical research machine learning platform, have teamed up to accelerate medication discovery, development, and clinical trials. Abbott also just introduced an artificial intelligence- powered coronary imaging technology. AI platform can detect the severity of calcium-based blockages and evaluate channel diameter to improve decision- making during coronary stenting procedures.9

AI based - drug discovery

Biological testing of pharmaceutical compounds consumes enormous time in the drug development process. Novartis researchers employ ML algorithms on photographs to determine which chemicals are worth further investigating to speed up the screening process. Algorithms are significantly faster at revealing new data sets than traditional human analysis and laboratory tests. Unique and effective medications can be available sooner while simultaneously lowering the operating expenses associated with each compound's manual examination. The following are some of the top biopharmaceutical companies' current AI initiatives:

[a] mobile platform to improve health outcomes - the ability to refer patients based on real-time data, improving patient outcomes.

[b] drug development- pharmaceutical corporations collaborate with software businesses to employ cutting-edge technologies in the costly and time-consuming drug discovery process.9

AI support antibiotic study

Antibiotic discovery has become more complicated in recent years with the rise of antibiotic resistance. Earlier, antibiotics were discovered by screening soil- swelling microbes for secondary compounds prohibited bacterial growth. However, antibiotic development is currently hampered by the discovery of the same molecules repeatedly. Recently, a study showcasing machine learning to find new antibiotics was released, where researchers employ machine learning to anticipate antibacterial chemicals in silico from a database of over 107 million molecules. This antibiotic, known as "Halicin," is effective against various bacteria, including tuberculosis and difficult- to-treat types. Other medications could benefit from this strategy, such as those used to treat cancer or neurological illnesses.1

AI in diagnosis and treatment

Physicians can collect data using powerful machine learning techniques and analyze and evaluate patient healthcare data. Deep learning and machine learning are being used by healthcare practitioners worldwide to store patient data in a cloud securely, or a centralized storage mechanism Electronic Medical Records (EMRs) are the term for this. Physicians can use these health records to determine how a specific genetic trait affects a patient's health. Machine Learning algorithms can use data contained in EMRs to provide real-time estimates for diagnostic purposes and suggest appropriate treatment for the patient. Verge Genomics is tackling the major issues in drug discovery by employing automated data collection and analysis. In other words, they're using an algorithm to map out hundreds of genes involved in brain disorders such as Alzheimer's, Parkinson's, and ALS (Amyotrophic lateral sclerosis). Medications could benefit from this strategy, such as those used to treat cancer or neurological illnesses.10

They believe collecting and interpreting gene data will positively impact the drug discovery phase, beginning with preclinical trials. Starting in the preclinical stage, utilize AI to track the effects of various pharmacological treatments on the human brain. As a result, drug companies can better understand a medicine's impact on human cells earlier in the development process. Verge genomics, in particular, use artificial intelligence to track the effects of various drugs on the human brain with a specific focus on the preclinical phase.10

Treatment and management of rare diseases

Advances in information technology, particularly in the fields of artificial intelligence (AI) and machine learning, large, multivariate datasets are frequently used to "train" AI and machine learning algorithms, which are subsequently used to make predictions on new data. For example, by classifying tumours in radiological images as benign or malignant.10

Advances in AI have rekindled interest in cures for rare diseases. There are currently over 350 million people worldwide who suffer from over 7,000 uncommon diseases. Heal, a UK-based biotech business has acquired $10 million in Series A funding to employ AI to discover breakthrough treatments for rare diseases, so it is not all doom and gloom for people with uncommon conditions. Another Swiss biotech start-up, Thera chon, has acquired $60 million in investment to create medications to treat rare genetic illnesses using AI.6,12 Artificial intelligence/machine learning (AI/ML) and its accompanying capabilities have opened up lots of new prospects for intelligent intervention, which, when properly harnessed, can greatly improve the rare disease treatment path.12

Continuous manufacturing in pharma

Continuous manufacturing refers to the production of a pharmaceutical product in a single continuous process. The entire process takes place in one location, from beginning to end, with no waiting times. Continuous manufacturing is a more flexible method that allows for better production scaling. For example, scaling up simply means running the continuous production process for a more extended period.13 In other words, continuous manufacturing makes matching supply to demand much more manageable than producing in batches.

Currently, traditional "batch" procedures are used to manufacture

most pharmaceuticals. Batch operations allow raw components to be added into the network at the beginning of the process and subsequently ejected as a final product together at once later. The finished batch must have consistent qualities and meet predetermined quality criteria. Between every production phase, the intermediate product is collected and frequently moved for the next step, which comprises several independent procedures (blending, granulation, drying, and so on). Batch production is a time-consuming, disjointed process that lacks agility and flexibility.14

On the other hand, continuous manufacturing techniques allow essential raw materials to be continually fed into the process on a regular basis, and the outcome continuously gets cleared. Compared to batch manufacturing, continuous processing is more adaptable, allowing it to adjust to fluctuations in economics more quickly. This is especially useful in times of crisis, such as when there are crucial drug shortages or pandemics. By running the process for extended periods, using parallel processing lines, or boosting the pace of the process, continuous manufacturing can theoretically allow faster output volume increases.14

Relevance of continuous manufacturing during covid-19 pandemic

During this life-threatening pandemic of covid-19, the pharmaceutical industries face unprecedented challenges, reinforcing the need for rapid, efficient, and scalable drug development and production. At this critical juncture in global health, when demand for low-cost vaccines and other pandemic-related treatments is at an all-time high, continuous manufacturing can assist in meeting that demand,

Figure 3. The several steps of data processing and the way to realizing Industry 4.0.18 as all major pharmaceutical companies are stepping up for continuous manufacturing.15

Factors that are causing continuous manufacturing to gain traction

Small batch industrial production, characterized by the sequential framework of large tanks, controlled individually for each procedure, has been the standard approach to producers in the medicinal and fine chemicals companies. In contrast, continuous manufacturing, including big factories for industrial chemicals, hasn't been widely adopted. Continuous manufacturing technology is a flow production approach that uses a constant supply of raw materials to make or treat products without disruption while the production system is in operation.

So far, the pharmaceutical industry's transition from batch to continuous manufacturing has been slow.2,16

However, a problem concerning product quality arose in the United States during the mid-1990s, when defective batch-produced medications were introduced onto the market, becoming a public concern. Furthermore, batch manufacturing was lacking for future production adjustment capability, which has been noted as a negative, fueling the movement more towards a continuous manufacturing technology that allows for the creation of the requisite volume whenever needed. In 2004, the US(FDA) issued commercial guidance, including suggestions for continuous pharmaceutical production. The pharmaceuticals and fine chemical industries' use of continuous manufacturing was cited as an essential issue in its annual report in 2018.13

Future of continuous manufacturing

Continuous manufacturing will be an evolution rather than a revolution. Some pharmaceutical companies have already adopted continuous technologies. Still, industry experts predict that it will be another five to ten years before fully integrated continuous biomanufacturing is commonly employed commercially.16,17

Pharma Industry 4.0

The 4th industrial revolution, known as Industry 4.0, combines fast-evolving technology such as the

Figure 4. A cyber-physical system (CPS) representation for futuristic pharmaceutical manufacturing 4.0.20 internet of networks, artificial intelligence, robotic systems, and powerful computing to disrupt the manufacturing landscape significantly. In a nutshell, automated, independent, and self-organizing production systems define Industry 4.0. It may not be simple to implement various new technologies to allow Industry 4.0. It may be valuable because it can boost output, improve production safety, improve quality, provide better value characteristics, offer flexibility, and decrease waste. Pharma industry 4.0 is a paradigm for tailoring digital solutions to the specific needs of the pharmaceutical industry. In practice, this translates to increased connectivity, increased efficiency, easier compliance, and the marshaling of production data to address problems as they arise. Equipment, PAT instruments, and real- time release testing (RTRt) make up a production floor).3,18 Using the internet the local networking and storage are connected to the unit operations. In Industry 4.0, a cyber-physical system (CPS) for drug industry includes three types of cloud computing: cloud provider, cloud platform, and manufacturing floor. External consumers can also use application services in the public cloud. The data for significantly greater elements like remote surveillance systems and manufacturing, monitoring and controlling, results from the laboratory, and modeling as well as experiments are stored in the cloud platform.19

The core idea is that CPS connects and regulates all of the value chain processes. Gadgets may, for example, forecast faults and initiate maintenance operations on their own or self-organize operations in response to changes in output.

Integrating internet, artificial intelligence, and automation empower systems to function with little or no personal participation. There are the quintessential aspects of Industry 4.0. To maximize manufacturing and corporation management, linked automated and robotics combine manufacturing systems with authentic online data and artificial intelligence. Interconnecting external and internal communication, multiple sources can be linked simultaneously. Internal data, including control of vitality and resources, outcomes of modelling and simulations, and laboratory values for pharmaceutical industries, could be integrated with data sources, such as consumer satisfaction, consumer expectations, vendor stocks, and outbreaks.

It is feasible to achieve exceptional real-time response, monitoring, control, and forecasting by combining multiple data sources. The result is a highly digitalized ecosystem and pharmacy value chain for producers.3

An Industry 4.0 smart factory's fundamental techniques

Two critical technologies are employed to acquire and store data from a manufacturing process:Computer storage technology, like the networking cloud, and information acquisition technique in-

cluding improved sensors utilized in operations, are both available. Computer storage technologies allow the long-term preservation of digitized data collected. Multidisciplinary robotics that is intelligent, precise, and real-time and enhanced or virtual reality systems enable intelligence, correctness, and real-time manufacturing. The modern broadband access network and proper encryption permit the factory.20

Cluster-based research

The emergence and growth of pharmaceutical clusters are examples of radical reforms in the pharmaceutical sector, which leads to increased market concentration and competition for all market participants.6

A critical feature of pharmaceutical clusters is that the organizations increase both their competitive advantage and the competitive advantage of the cluster itself by complementing one another. Clusters are most common in the United States of America and Europe. Clusters are typically based on universities and research institutes. Regional budgets provide primary capital, with additional funding provided by attracting investments. For the cluster policy within the European Union, the European Institute of Technology and Innovation contributes to its development. The main direction of cluster policy in European countries over the past five years is the unification of innovations and support for government procurement for product development. Clusters tend to occur in under developed areas. The development and growth of pharmaceutical clusters as a territory's innovative activity revealed that more than ten pharmaceutical clusters are currently of interest to well-known members of the global pharmaceutical industry. The Kaluga Pharma

Cluster, for example, is a research centre that

focuses on biomedicine. and biotechnology.6 The Pharmaceutical Solid State Research Cluster (PSSRC) was developed to stimulate solid-state research by sharing facilities, working on specific projects, and allowing research students to interact with other academics in the field.

Synthesis and Solid-State Pharma Cluster (SSPC)is a Science Foundation Ireland (SFI) and industry- funded Global Hub of Pharmaceutical Process Innovation and Advanced Manufacturing in Ireland. It is one type of collaboration, with 24 industries, nine research organizations, and 12 international scientific collaborators. The SSPC's mission is to bring together skilled scientists from academics and the pharmaceutical sector to tackle pressing research issues.21,22

The cluster's research activities are focused on two key areas: the development of breakthrough analytical technologies using Artificial Intelligence/ Machine learning and their application to advanced process engineering of conventional pharmaceutical unit operations. As technology evolves, Advanced and futuristic career options develop, dramatically increasing the industrial production of medicines and bringing the next generation of pharmaceuticals with new research. Advanced and futuristic careers in pharmaceuticals include Continuous manufacturing, AI in pharma, Industry 4.0 in pharma, Cluster-based research centers.4,23

Indian pharma company overview

As a leading producer of low-cost, high-quality generic drugs, India supplies roughly 20% of global pharmaceutical demand in terms of volume. The entire industry is 45 billion US dollars with 24 billion US dollars exports. Between 2020 and 2045, the economy is expected to grow by 600%. Generic drugs have traditionally been India's stronghold, accounting for more than 70% of total market revenue. Outside of North America, India has the highest number of US FDA-approved generic drug manufacturing plants. Howeve r, the recent coronavirus (COVID-19) pandemic has revealed weak links in the Indian pharmaceutical sector.24

Conclusion

Finally, it seems like artificial intelligence and machine learning have a lot of promise for the pharmaceutical sector. Artificial intelligence (AI) and machine learning (ML) are becoming more mainstream in the pharmaceutical industry, which means they will soon be accessible to smaller and medium-sized businesses. To meet the increasing need for medications, advanced pharmaceutical jobs could be the way to go. When the pharmaceutical business uses technology, it has the potential to completely transform the economy of the nation. Artificial intelligence isn't just reshaping the pharmaceutical sector; it's also providing medication firms with fresh opportunities to elevate their brand value. To help meet the increasing global need for medicines, for instance, one career option is continuous production. Advancements in R&D may be facilitated by artificial intelligence (AI). The computerization of production and the enhancement of cluster competitiveness are both facilitated by developments in Industry 4.0.Economic growth is another area that might benefit from cluster-based research. All things considered, a career in advanced pharmaceuticals has the potential to revolutionize the pharmaceutical industry.

REFERENCES

1. First published in 2021 by Patel, J., Patel, D., and Meshram, D. The Emergence of AI in the Pharmaceutical Sector. Published in the Journal of Advancement in Pharmacognosy, volume 1, issue 2, 2015.

Plumb, K. (2005) 2. Rethinking the role of continuous processing in the pharmaceutical sector. Publication: Chemical Engineering Research and Design, Volume 83, Issue 6, A.

Thirdly, Ding (2018). Sustainable pharmaceutical supply chains: a literature analysis and potential areas for future study in the 4.0 pharmaceutical industry. Environmental Protection and Process Safety, 119.

4. The authors of the publication are Balasegaram, Menon, Olliaro, Sablinski, Thomas, Todd, H., Torreele, and Wilbanks (2017). A pharmaceutical pathway that is open source. The publication is PLoS Medicine, volume 14, issue 4, chap. 14.

Fifth, Ekins (2016). "Deep Learning in Pharmaceutical Research: The Next Era" (33(11)).

6. It was written by Patrusheva in 2019. REGIONAL INDUSTRIAL CLUSTER OPERATIONSTUDY. 2. International Scientific Conference on Social Sciences, Sixth SWS ISCSS 2019, 2.

7. As per the 2019 publication by Arvapalli, Krishnaveni, Divya K., and Sharma, J. V. C. Review of Artificial Intelligence in the Pharmaceutical Sector. Publication: 7(10), International Journal of Innovative Pharmaceutical Sciences and Research.

Babu, K. A., MS, S., and AS, M. D. (2010). Pharma Artificial Intelligence. Publication: International Journal of Current Research in Physiology and Pharmacology (IJCRPP).

This information is derived from the work of Arinez, Chang, Gao, Xu, and Zhang (2020). Current State and Future Prospects of Artificial Intelligence in Advanced Manufacturing. Article 142(11) of the Journal of Manufacturing Science and Engineering published in the Transactions of the ASME.

10. Gupta, A. (2018). How AI is Changing the Pharmaceutical Industry. Published in the Journal of Pharmacovigilance, volume 6, issue 2, in 2007.

11. Lamberti et al. (2019) reported in the following publications: Wilkinson, Donzanti, Parikh, Wilkins, and Getz. An Investigation on the Potential and Actual Use of AI in the Pharmaceutical Industry. Journal of Clinical Therapeutics, 41(8).

The authors of the 2020 article are Ulfa, Saputra, Yuswardi, and Nguyen. The function of AI in the pharmaceutical industry. Published in the seventh issue of the journal critical reviews.

In 2015, the following authors were involved: Walde, J., Godawat, R., Hwang, C., Abe, Y., Sinclair, A., Konstantinov, K., Rohani, M., Warikoo, V., Zydney, A. L., Chan, S., Titchener-Hooker, N., Sørensen, E., Helling, C., Ditz, R., Strube, J., Jungbauer, A., Taylor, M. J., Tanna, S., Sahota, T., Zydney, A. L. (2015). FDA Perspective on Continuous Manufacturing. This article is from the Journal of Biotechnology, volume 213, issue 10, page.

In 2018, Cole and Johnson published a paper. Methods of production that use continuous flow rather than batch-by-batch

chemicals used in medicine. Journal of Clinical Pharmacology: An Expert Review, 11(1).

15. In a study conducted by Helal, Elnoweam, Eassa, Amer, Eltokhy, Fayyaz, and Nounou, the authors were 15.

I. in the year 2019. Pharmaceutical industry's integrated continuous manufacturing: present evolutionary stages toward revolutionary future. Drug and Medical Devices Patent Analyst, 8(4).

16. In 2015, Lee et al. recorded the following: O'Connor T. F., Yang X., Cruz C. N., Chatterjee S., Madurawe R. D., Moore C. M. V., Yu L. X., and Woodcock J. Transitioning Pharmaceutical Production to Continuous Manufacturing: A Modern Approach. As published in the Journal of Pharmaceutical Innovation (Volume 10, Issue 3). Baxendale, I. R., Florence, A. J., Braatz, R. D., and Hodnett, 17.

J. P. Sherlock, B. K. Jensen, M. D. Johnson, P. Sharratt, and K. F. Jensen (2014). Methods and Tools for Continual Pharmaceutical Production: Synthesis, Work-Up, and Substance Isolation. Research Report, 1.

18. In a recent publication by Arnold, Tyner, Yu, Lee, and Kopcha (2021), the authors highlight the importance of a specific approach. The fourth industrial revolution and its implications for the pharmaceutical industry: Future-proofing smart factories. Published in the International Journal of Pharmaceutics, Section 602.

In 2020, Reinhardt, Oliveira, and Ring published a study. Present-Day Views on the Progress of Industry

4.0 in the Health Care Industry. Article published in the Journal of Industrial Information Integration, volume 18, page 18.

In 2020, Goshain and Sharma published a study. Current pharmaceutical industry research priorities and obstacles: 4.0. Publication: International Journal of Research in Pharmaceutical Sciences, Volume 11, Issue 4, October 2018.

aldridge (2008), page 21. Pharmaceuticals in Ireland: Towards the Future. Pharmacological Research in Europe, Volume 20, Issue 2.

Twenty-two. Lofgren, H. (2009). The Irish experience with pharmaceutical policy and investment. No. 33(2) of the Australian Health Review.

The authors of this piece are Daemmrich and Bowden (2005). The First Decade of Modern Pharmaceutical Research and Development, 1870–1930. The latest news in chemical and engineering technology.

Das and Das (2015) were cited in item 24. Factoinfluencing pharmaceutical R&D in India due to intense competition. RULE,